

## EQA round: GP2/23 - Detection of Monoclonal Components

Deadline: 22.9.2023

Setup: groups - manufacturer of kit

AV = assigned value

N<sub>tot</sub> = total number of the resultsN<sub>eva</sub> = number of the results assessed

CVP = consensus of all participants

N<sub>rel</sub> = relative number of the resultsN<sub>suc</sub> = number of successful results

&gt;&gt;&gt; ... expected result

S<sub>rel</sub> = relative success

&gt; ... acceptable result

± ... result not assessed

Test Sample Group	Frequency of the results				Success		
	AV	N <sub>tot</sub>	N <sub>rel</sub> [%]	Result	N <sub>eva</sub>	N <sub>suc</sub>	S <sub>rel</sub> [%]
<b>(246) Gammopathies (typisation)</b>		93			93	72	77
<b>Sample A</b>		93			93	83	89
(12) Beckman Coulter		1	1,1	IgA-kappa; kappa-free			
(34) Sebia	CVP >>>	59	63	IgA-kappa			
		5	5,4	IgA-kappa; kappa-free			
		1	1,1	IgM-kappa			
(100) Helena	CVP >>>	1	1,1	IgA-kappa			
(213) Interlab Srl	CVP >>>	23	25	IgA-kappa			
		1	1,1	IgA-kappa; IgG-kappa			
		1	1,1	IgA-kappa; kappa-free			
		1	1,1	IgG-kappa			
<b>Sample B</b>		93			93	82	88
(12) Beckman Coulter	CVP >>>	1	1,1	kappa-free			
(34) Sebia		4	4,3	Not specified			
	>	7	7,5	kappa			
	CVP >>>	41	44	kappa-free			
	CVP >>>	13	14	kappa-free; kappa			
(100) Helena	CVP >>>	1	1,1	kappa-free; kappa			
(213) Interlab Srl		7	7,5	Not specified			
	>	2	2,2	kappa			
	CVP >>>	11	12	kappa-free			
	CVP >>>	6	6,5	kappa-free; kappa			